IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Raymond James Trust N.A.

Raymond James Trust N.A. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,361 shares of the medical research company’s stock after selling 112 shares during the quarter. Raymond James Trust N.A.’s holdings in IQVIA were worth $2,614,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Los Angeles Capital Management LLC boosted its stake in shares of IQVIA by 17.5% during the 4th quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock worth $27,445,000 after purchasing an additional 17,677 shares during the last quarter. Jennison Associates LLC grew its stake in IQVIA by 7.3% in the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock worth $35,636,000 after acquiring an additional 9,578 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in IQVIA by 4.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock valued at $532,070,000 after acquiring an additional 93,194 shares during the last quarter. Cadian Capital Management LP acquired a new stake in shares of IQVIA during the fourth quarter worth $70,108,000. Finally, Nomura Holdings Inc. purchased a new stake in shares of IQVIA in the fourth quarter valued at $857,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research note on Monday, August 19th. Morgan Stanley upped their price target on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. JPMorgan Chase & Co. increased their target price on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Finally, The Goldman Sachs Group started coverage on IQVIA in a research note on Thursday, June 6th. They set a “buy” rating and a $270.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $265.67.

IQVIA Stock Performance

Shares of NYSE:IQV traded up $0.01 during trading on Monday, reaching $248.94. 16,189 shares of the company’s stock traded hands, compared to its average volume of 1,059,540. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The company has a 50 day moving average of $227.79 and a 200-day moving average of $233.32. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The stock has a market capitalization of $45.38 billion, a P/E ratio of 34.01, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49.

IQVIA (NYSE:IQV) last announced its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business posted $2.22 earnings per share. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.24 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.